0PNT Acacia Pharma Group Plc

 
TIDMACPH 
 
   Christine Soden to step down and Gary G. Gemignani to be appointed as 
new CFO 
 
   This announcement contains inside information for the purposes of 
Article 7 of the Market Abuse Regulation (EU) No 596/2014. 
 
   Cambridge, UK and Indianapolis, US -- 13 January 2020: Acacia Pharma 
Group plc ("Acacia Pharma", the "Company", the "Group"), (EURONEXT: 
ACPH), a pharmaceutical company developing and commercialising hospital 
products for US and international markets, announces a planned 
succession of its Chief Financial Officer role. Christine Soden will 
step down as CFO and retire from the Board on 29 February 2020. She will 
be succeeded in the CFO role by Gary G. Gemignani, who began working 
with the Group this year. 
 
   The planned succession has been implemented after the Company closed a 
strategic transaction with Cosmo Pharmaceuticals N.V. (announced on 10 
January 2020) and ahead of the upcoming reviews of the New Drug 
Applications (NDA) for BARHEMSYS(R) (intravenous amisulpride) and the 
newly in-licensed ByFavo(TM) (remimazolam) by the US Food and Drug 
Administration (FDA), with decisions expected no later than 26 February 
2020 and 5 April 2020, respectively. This will allow for a smooth 
transition period as the Company further refines and drives its 
commercial strategy and strengthens its operational team and expertise 
in the US ahead of these milestones. 
 
   Gary Gemignani's career in healthcare spans over three decades, 
including senior management/executive positions at several 
pharmaceutical and biopharmaceutical companies. Most recently, he served 
as CFO of Synergy Pharmaceuticals Inc. where he successfully led the 
sale of this Nasdaq-listed company's assets to Bausch Health. 
 
   Previously, he served as CEO and CFO of Biodel Inc., overseeing business 
and strategic planning, operations and financing activities of the 
company. During his tenure, Gary successfully led Biodel's reverse 
merger with Albireo Ltd and managed several corporate restructurings to 
strengthen Albireo's overall financial position. Prior to this, he 
served in senior and executive financial and operational roles with 
multiple public and private companies including, Gentium, Novartis and 
Wyeth. Mr Gemignani started his career at Arthur Andersen & Co. 
 
   Mike Bolinder, CEO of Acacia Pharma, said: "I would first sincerely like 
to thank Christine, on behalf of the Board and the management team, for 
all she has done for us over the past five years. Our company has 
benefited greatly from her financial and operational leadership during 
her tenure and we wish her well in her future endeavours." 
 
   Mike Bolinder added: "We are very fortunate that Gary has joined Acacia 
Pharma in this critical leadership role of CFO as we move into the 
commercial stage of the Company's lifecycle. Gary brings extensive 
expertise in financial and operational management, business development 
and strategic planning to Acacia Pharma, and a proven track record of 
driving value. We look forward to Gary's contributions as we move 
towards the anticipated launches of BARHEMSYS and ByFavo." 
 
   "I am excited to join Acacia at such a transformative time for the 
business," said Gary Gemignani. "I look forward to working with Mike and 
his team of talented employees to maximise the value of both BARHEMSYS 
and ByFavo. This is an opportunity to be a part of a company that is 
passionate, highly energised and committed to making a real difference 
to improving the lives of patients." 
 
   Contacts 
 
   Acacia Pharma Group plc 
 
   Mike Bolinder, CEO 
 
   Christine Soden, CFO 
 
   +44 1223 919760 
 
   IR@acaciapharma.com 
 
   Citigate Dewe Rogerson (Financial PR) 
 
   Mark Swallow, Frazer Hall, David Dible 
 
   +44 20 7638 9571 
 
   acaciapharma@citigatedewerogerson.com 
 
   About Acacia Pharma 
 
   Acacia Pharma is a hospital pharmaceutical company focused on the 
development and commercialization of new products designed to improve 
the treatment and care of surgical and cancer patients. The Group's 
pipeline includes near-market opportunities, which it plans to sell 
directly in the US through its own commercial operations, and in other 
territories through licensing and distribution agreements with selected 
partners. 
 
   The Group's pipeline includes: 
 
 
   -- BARHEMSYS(R) (intravenous amisulpride) for post-operative nausea & 
      vomiting (PONV) (NDA filed) 
 
   -- ByFavo(TM) (remimazolam), an ultra-short-acting and reversible 
      intravenous sedative/anaesthetic designed for use during invasive medical 
      procedures, such as during colonoscopy and bronchoscopy (NDA filed), and 
 
   -- APD403 (amisulpride) for chemotherapy induced nausea & vomiting (CINV) 
      (Phase 2) 
 
 
   Acacia Pharma is based in Cambridge, UK and Indianapolis, IN. The 
Company is listed on the Euronext Brussels exchange under the under ISIN 
code GB00BYWF9Y76 and ticker symbol ACPH. 
https://www.globenewswire.com/Tracker?data=XKMccO6cOQGCYeB7MUUIWXCqNiU6ro9HEktEB2klzYyFSxu85D1pfT1Ayyr0KHIkp20bbcbawt4ZhVcf1jaYaN_3yrkGLjFykIp_OmpqaRs= 
www.acaciapharma.com 
 
   Forward looking statement 
 
   This announcement includes forward-looking statements, which are based 
on current expectations and projections about future events. These 
statements may include, without limitation, any statements preceded by, 
followed by or including words such as "believe", "expect", "intend", 
"may", "plan", "will", "should", "could" and other words and terms of 
similar meaning or the negative thereof. Forward-looking statements may 
and often do differ materially from actual results. These 
forward-looking statements are subject to risks, uncertainties and 
assumptions about the Company and its subsidiaries and investments, 
including, among other things, the development of its business, trends 
in its operating industry, and future capital expenditures and 
acquisitions. By their nature, forward-looking statements involve risk 
and uncertainty because they relate to future events and circumstances. 
Any forward-looking statements reflect the Company's current view with 
respect to future events and are subject to risks relating to future 
events and other risks, uncertainties and assumptions relating to the 
Group's business, results of operations, financial position, prospectus, 
growth or strategies and the industry in which it operates. Save as 
required by law or applicable regulation, the Company and its affiliates 
expressly disclaim any obligation or undertaking to update, review or 
revise any forward-looking statement contained in this announcement 
whether as a result of new information, future developments or 
otherwise. Forward-looking statements speak only as of the date they are 
made. 
 
 
 
 

(END) Dow Jones Newswires

January 13, 2020 01:00 ET (06:00 GMT)

Grafico Azioni Acacia Pharma (LSE:0PNT)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Acacia Pharma (LSE:0PNT)
Storico
Da Apr 2023 a Apr 2024